FREE REPORT
www.biotechfreereports.com
Aerie
Pharmaceuticals, Inc.
(NASDAQ: AERI)
Why Analysts Believe This Small Ocular
Concern Can Double
This week’s free report is on a small ocular concern that has a very
favorable risk/reward outlook at current trading levels. The company
also has a few “shots on goal,” upcoming near term catalysts and
increasingly positive analyst support.